Coronavirus Disease 2019 (COVID-19) Analyst Consensus Global Drug Sales Forecast – Q2, 2021

This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Currently there are 37 drugs indicated for COVID-19 which have analyst consensus forecasts available.

Scope

This 41-page report gives important, expert insight you won’t find in any other source. 14 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is required reading for:

Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in

Companies that are interested in entering the COVID-19 disease space

Large pharma companies with investment groups or BD teams looking for partnership opportunities in the COVID-19 disease space

Reasons to buy

Analysis of COVID-19 analyst consensus sales forecasts

Overview of Pipeline portfolio of companies involved in COVID-19 disease space

Detailed Analysis of how COVID-19 have affected analyst consensus sales forecasts for previously forecasted Drugs

Companies mentioned

Altimmune Inc

Arcturus Therapeutics Ltd

AstraZeneca Plc

Atea Pharmaceuticals Inc

Atossa Therapeutics Inc

BioNTech SE

CanSino Biologics Inc

Capricor Therapeutics Inc

ContraFect Corp

Curevac NV

Dynavax Technologies Corp

Eiger BioPharmaceuticals Inc

Eli Lilly and Co

Enlivex Therapeutics Ltd

Evelo Biosciences Inc

F. Hoffmann-La Roche Ltd

Galecto Inc

Genexine Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Heat Biologics Inc

I-Mab

Immunic Inc

Immunome Inc

InflaRx NV

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kiniksa Pharmaceuticals Ltd

Merck & Co Inc

Moderna Inc

Molecular Partners AG

Novavax Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Shionogi & Co Ltd

TFF Pharmaceuticals Inc

Valneva SE

Vir Biotechnology Inc

Table of Contents

1 COVID-19 Global Analyst Consensus Sales Forecast

1.1 COVID-19 Prophylactic Vaccines with Global Analyst Consensus Sales Forecast

1.2 COVID-19 Therapeutic Drugs with Global Analyst Consensus Sales Forecast

1.3 COVID-19 Global Analyst Consensus Sales Forecast

1.4 Top Three Marketed COVID-19 Drugs with Peak Forecast: Global Analyst Consensus Sales Forecast

2 COVID-19 Prophylactic Vaccine and Therapeutic Drugs: Global Analyst Consensus Sales Forecasts

2.1 COVID-19 Prophylactic Vaccine Global Analyst Consensus Sales Forecast

2.2 COVID-19 Therapeutic Drugs Global Analyst Consensus Sales Forecast

3 BioNTech SE

3.1 Global Analyst Consensus Sales Forecast – Comirnaty

3.2 Percentage Change from Q1 2021 to Q2 2021 Global Analyst Consensus Sales Forecast-Comirnaty

4 Moderna

4.1 Global Analyst Consensus Sales Forecast – mRNA-1273

4.2 Percentage Change from Q1 2021 to Q2 2021 Global Analyst Consensus Sales Forecast – mRNA-1273

5 Johnson & Johnson

5.1 Global Analyst Consensus Sales Forecast – COVID-19 Vaccine

6 Gilead Sciences

6.1 Global Analyst Consensus Sales Forecast – Veklury

6.2 Percentage Change from Q1 2021 to Q2 2021 Global Analyst Consensus Sales Forecast – Veklury

7 Eli Lilly

7.1 Global Analyst Consensus Sales Forecast – Bamlanivimab/Etesevimab

8 Key Findings

Appendix

9.1 Abbreviations

9.2 Methodology

9.3 Related Reports

9.4 About the Authors

9.5 About GlobalData

9.6 Contact Us

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports